相关实验视频
Updated: May 23, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
血小板上车血管破坏剂用于自我放大瘤向治疗
Hongyu Chu1,2,3, Yajun Xu2,3, Yuezhan Shan1,2,3
1Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Journal of nanobiotechnology
|March 10, 2025
概括
一种基于血小板的新型药物递送系统,P@NPPD,可以提高DMXAA (5,6-二甲基甘-4-酸) 的瘤向和抗癌疗效,同时降低毒性.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 癌症治疗 癌症治疗
背景情况:
- 5,6-二甲基甘-4-酸 (DMXAA) 是一种具有抗癌性质的血管破坏剂.
- DMXAA的临床使用受限于针对性差以及心血管方面的副作用.
- 血小板具有天然的瘤定位能力.
研究的目的:
- 为DMXAA开发一种新的自我放大瘤向传递系统 (P@NPPD).
- 为了提高DMXAA的瘤特异性,并减少系统性毒性.
- 评估P@NPPD.的治疗疗效和免疫激活潜力.
主要方法:
- 合成的亚化物功能化聚乙烯糖醇-b-聚-[N-2-基乙烯) -阿斯巴塔胺]-DMXAA (NPPD).
- 结合了NPPD与DBCO修饰的血小板,以产生P@NPPD.
- 研究了P@NPPD的瘤向,药物释放以及体内抗癌效应.
主要成果:
- P@NPPD显示增强了瘤向效率 (增加了2.61倍).
- 取得了89.1%的显著瘤抑制率.
- P@NPPD有效地激活了局部免疫反应,改善了治疗结果.
结论:
- P@NPPD代表了针对性癌症治疗的有希望的平台.
- 该系统增强了DMXAA向瘤的传递,并最大限度地降低了全身毒性.
- 通过向药物输送和免疫激活,P@NPPD提供了更好的治疗疗效和安全性.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
448
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
448
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K

